Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATI 2138

Next Previous
Search
Drug Profile

ATI 2138

Alternative Names: ATI-2138

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Confluence Life Sciences
  • Developer Aclaris Therapeutics; Confluence Life Sciences
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Ulcerative colitis
  • Research Autoimmune disorders
  • No development reported Arthritis; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 19 Feb 2025 Pharmacodynamics data from a preclinical study released by Aclaris Therapeutics
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in USA (PO)
  • 19 Aug 2024 Phase-II clinical trials in Atopic dermatitis in USA (PO) (NCT06585202)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top